Exonbio

Exonbio is a private U.S. biotechnology services company focused on recombinant antibodies and recombinant proteins for research, diagnostic, and selected therapeutic antibody discovery applications. The company markets a proprietary Single Plasma cell INterrogation (SPIN) platform that uses microfluidics and single-cell analysis to isolate antigen-specific plasma cells and generate high-affinity monoclonal antibodies with broad epitope coverage. Exonbio appears to operate primarily as a contract research and antibody development partner rather than as a developer of proprietary clinical drug candidates. Its offerings include antibody discovery, IVD antibody development, anti-idiotype antibody development, PTM antibody development, and large-scale antibody production. The company also sells infectious disease and other assay-enabling reagents, including antibodies and antigens for SARS-CoV-2, influenza, RSV, Ebola, tuberculosis, H. pylori, Streptococcus pneumoniae, and HbA1c-related applications.